longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Humacyte

HUMA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Weekly Recap | Humacyte -6.95%, consensus target above spot

    Weekly Review·Sep 5 at 07:04 AM
    HUMA+0.89%
  • The Nasdaq Biotechnology Index fell by more than 1.2%. Among them, Medpace dropped 15.90%, Tectonic Therapeutic fell 15.22%, Regenxbio decreased 14.31%, Humacyte declined 13.93%, and Anavex Life Sciences fell 8.74%. In contrast, Mesoblast rose 7.21%, Personalis increased 10.03%, Invivyd gained 10.14%, PepGen surged 17.99%, and Neumora Therapeutics jumped 25.10%

    Wallstreetcn·Feb 10 at 11:10 PM
    IDNA+3.36%RGNX+2.94%